-
11.发明授权公开(公告)号：US11814685B2
公开(公告)日：2023-11-14
申请号：US16758624
申请日：2018-10-24
申请人： UNIVERSITÉ PARIS CITÉ , INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.)
IPC分类号： C12Q1/6886
CPC分类号： C12Q1/6886 , C12Q2600/118 , C12Q2600/158 , C12Q2600/178
摘要： This invention relates to a method for diagnosing and/or prognosticating HER2-dependent cancer in a subject, comprising a) measuring the amount of one or more miRNA selected from the group consisting of miRNA 429-3p, miRNA 29c-3p, miRNA 29a-3p, miRNA 29b-3p, miRNA 200a-3p, miRNA 200b-3p, miRNA 200c-3p, miRNA 141-3p, miRNA 15a-5p, miRNA 15b-5p, miRNA 16-5p, miRNA 424-5p, miRNA 497-5p, miRNA 615-3p, miRNA 451a-3p and miRNA 542-5p in a sample from the subject; b) comparing the amount of one or more miRNA measured in step a) to a reference value; c) finding a deviation or no deviation of the amount of one or more miRNA measured in step a) from the reference value; and d) attributing said finding of deviation or no deviation to a particular diagnosis and/or prognosis of HER2-dependent cancer in the subject.
-
公开(公告)号：US20230340085A1
公开(公告)日：2023-10-26
申请号：US18174182
申请日：2023-02-24
申请人： INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) , UNIVERSITÉ CLAUDE BERNARD LYON 1 , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE , ECOLE NORMALE SUPERIEURE DE LYON
IPC分类号： A61P35/00 , C12N15/62 , C12N15/86 , C07K16/00 , C07K16/10 , A61K39/29 , A61P37/02 , C12N15/85 , A61P31/00 , C12N15/113
CPC分类号： C07K16/109 , A61K39/29 , A61P31/00 , A61P35/00 , A61P37/02 , C07K16/00 , C12N15/113 , C12N15/62 , C12N15/85 , C12N15/86 , A61K2039/505
摘要： The invention concerns a multicistronic nucleic acid, in particular an isolated multicistronic nucleic acid, comprising: A) a sequence comprising successively: A1) a sequence encoding the light chain variable domain of an antibody of interest, fused in the frame with A2) a sequence encoding the constant region of the light chain of an immunoglobulin Ig; and B) a sequence compris -ing successively: B1) a sequence encoding the heavy chain variable domain of said antibody of interest, fused in the frame with B2) a sequence encoding the constant regions of the heavy chain of an immunoglobulin Ig′ in secretory form; B3) an intronic sequence of the gene of the heavy chain of said immunoglobulin Ig′, said intronic sequence comprising an internal 5′ splice site enabling the spli -cing of said intronic sequence B3) and a secretory-specific poly(A) (p AS) signal from the 3′ terminal exon of said gene; B4) a se -quence, in frame with sequence B1), encoding the transmembrane and cytoplasmic domains M1 and M2 of the immunoglobulin Ig′ BCR, wherein said sequence B4) comprises, between the coding sequences of the M1 and M2 domains, an intronic sequence containing a splice site enabling the splicing of said intronic sequence between the M1 and M2 domains coding sequences; and B5) a membrane-anchored specific poly(A) signal (p AM), after the stop codon of the M2 domain, wherein the multicistronic nucleic acid enables the co-expression of the sequences A and B into separate proteins.
-
公开(公告)号：US20230296708A1
公开(公告)日：2023-09-21
申请号：US17697492
申请日：2022-03-17
申请人： Siemens Healthcare GmbH , Centre National de la Recherche Scientifique (CNRS) , Institut National de La Sante et de la Recherche Medicale (INSERM) , King's College London , Department of Health and Human Services , Univ Paris XIII Paris-Nord Villetaneuse , Universite de Paris
发明人： Giacomo Annio , Verena Muller-Reinwald , Ralph Sinkus , Omar Darwish , Wilfried Schnell , Tamara Elisabeth Falkner , Ahmed M. Gharib
CPC分类号： A61B6/0487 , A61B5/055 , G01R33/48
摘要： The present disclosure is directed to a motor for a magnetic resonance (MR) tomography room, to a patient table for the MR room, to a MR elastography device, and to a MR tomography device. A MR tomography device for a MR elastography imaging protocol is arranged within the MR tomography room, and includes a rotational drive for supplying rotational energy to power a MR elastography transducer usable during the MR elastography imaging protocol, and a support structure. The rotational drive comprises a terminal for connecting the MR elastography transducer to the rotational drive, and a bearing means configured such that the position of the terminal relative to the support structure is adaptable along a trajectory predetermined by the bearing means. The rotational drive is mounted to the support structure via the bearing means.
-
公开(公告)号：US20230285381A1
公开(公告)日：2023-09-14
申请号：US18296543
申请日：2023-04-06
申请人： INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) , UNIVERSITÉ PARIS-SACLAY , ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (APHP) , HOPITAL MARIE LANNELONGUE
发明人： Sylvia COHEN-KAMINSKY , Marc HUMBERT , Sebastien DUMAS , Gilles BRU-MERCIER , Samir MESSAOUDI , Jean-Daniel BRION , Mouad ALAMI , Gilles GALVANI
IPC分类号： A61K31/46 , A61P9/12 , A61K45/06 , C07D451/00 , C07D451/02
CPC分类号： A61K31/46 , A61K45/06 , A61P9/12 , C07D451/00 , C07D451/02
摘要： The present invention relates to compounds of formula (I);
for use as peripheral NMDA receptor antagonists.-
公开(公告)号：US11708364B2
公开(公告)日：2023-07-25
申请号：US17216114
申请日：2021-03-29
申请人： AGV Discovery , Institut National de la Sante et de la Recherche Medicale (INSERM) , Centre National de la Recherche Scientifique (CNRS) , Universite De Montpellier
发明人： Jean-François Guichou , Cédric Bories , Clément Geoffroy , Charline Duquenne , Muriel Gelin , Gilles Labesse , Yannick Bessin , Loic Mathieu
IPC分类号： A61K31/4353 , C07D471/04 , A61P35/00 , C07D519/00 , C07F9/6561 , C07D491/048 , C07D491/113 , C07D491/107
CPC分类号： C07D471/04 , A61K31/4353 , A61P35/00 , C07D491/048 , C07D491/107 , C07D491/113 , C07D519/00 , C07F9/6561
摘要： The present invention concerns a compound of formula (I), or one of its pharmaceutically acceptable salts, especially for use as inhibitors of the ERK kinase activity in particular ERK2 activity, it also concerns prodrugs of these compounds.
-
公开(公告)号：US20230227818A1
公开(公告)日：2023-07-20
申请号：US17998442
申请日：2021-05-12
申请人： INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) , UNIVERSITE D'ANGERS , ICO (INSTITUT DE CANCÉROLOGIE DE L'OUEST)
IPC分类号： C12N15/11 , C12N15/113 , C12Q1/6827
CPC分类号： C12N15/111 , C12N15/1135 , C12Q1/6827 , C12N2310/20 , C12N2320/10
摘要： The invention relates to the field of personalized medicine, and the ability to administer targeted therapies consequently to biomarkers functional identification. In particular, the invention relates to the field of clinical applicable methods for the characterization, and especially the functional evaluation, of genetic variants in a patient. In particular, the invention relates to the field of the characterization, and classification, of variants of uncertain significance (VUS) or other unreported variants in patients. The in vitro method presented here is effective for the characterization of the functional impact of genetic variants in a patient, in particular of VUS, such as BRCA1 and BRCA2 VUS. The inventors have shown that this experimental framework can be used to obtain the necessary biological evidence of VUS function required for the prescription of targeted treatment within three weeks, which is compatible with use in clinical application.
-
公开(公告)号：US20230203534A1
公开(公告)日：2023-06-29
申请号：US17926709
申请日：2021-05-21
申请人： GENETHON , INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) , UNIVERSITE D'EVRY VAL D'ESSONNE , UNIVERSITE CLAUDE BERNARD LYON 1
发明人： Louisa JAUZE , Fabienne RAJAS , Giuseppe RONZITTI
CPC分类号： C12N15/86 , C07K14/8125 , C12N9/16 , C12Y301/03009 , C12N2750/14143 , C12N2750/14171
摘要： The invention relates to an adeno-associated virus (AAV) vector comprising a nucleic acid construct for the expression of a glucose-6-phosphatase-a (G6Pase-a) in a cell, the construct comprising a nucleic acid sequence encoding the G6Pase-a, wherein the nucleic acid sequence encoding the G6Pase-a is operably linked to a human alpha-1 antitrypsin (hAAT) promoter, a cell transformed with the vector of the invention, a composition comprising the vector or the cell of the invention, and the use thereof.
-
公开(公告)号：US11684640B2
公开(公告)日：2023-06-27
申请号：US16472778
申请日：2017-12-22
申请人： INSTITUT GUSTAVE ROUSSY , INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE-INSERM , UNIVERSITE PARIS-SACLAY , Institut national de recherche pour l'agriculture, l'alimentation et l'environnement (INRAE)
IPC分类号： A61K35/744 , A61K39/395 , C12Q1/6886 , C12Q1/689 , A61K39/00
CPC分类号： A61K35/744 , A61K39/39558 , C12Q1/689 , C12Q1/6886 , A61K2039/55594 , A61K2039/585 , C12Q2600/106 , C12Q2600/118
摘要： The invention relates to gut microbiota profiles associated with response or resistance to treatments with ICB, in particular with anti-PD1 or anti PD-L1 or anti-PD-L2 antibodies. In particular, the invention pertains to a theranostic method for identifying good responders, to whom an anti-PD1 or anti PD-L1 or anti-PD-L2 can be administered, while a pre-treatment based on FMT and/or immunogenic probiotics is recommended to bad responders exhibiting a dysbiosis. In particular, the present invention pertains to Akkermansia muciniphila as the main commensal species distinguishing responders from progressors and its use alone or with E. hirae for the treatment of antibiotics or gut repertoire insufficiency-associated dysbiosis.
-
公开(公告)号：US11680245B2
公开(公告)日：2023-06-20
申请号：US16463655
申请日：2017-11-30
发明人： James Di Santo , Ai Ing Lim
IPC分类号： G01N33/53 , C12N5/0789 , A61K49/00 , G01N33/50 , C12N5/0775 , G01N33/68 , G01N15/14
CPC分类号： C12N5/0647 , A61K49/0008 , C12N5/0662 , G01N15/14 , G01N33/5047 , G01N33/5094 , G01N33/6869 , C12N2501/2301 , C12N2501/2302 , C12N2501/2307
摘要： Innate lymphoid cells (ILCs) represent innate versions of T helper and cytotoxic T cells that differentiate from committed ILC precursors (ILCP). Still, how ILCP relate to mature tissue-resident ILCs remains unclear. ILCP that are present in the blood and all tested lymphoid and non-lymphoid human tissues were identified. Human ILCP fail to express the signature transcription factors (TF) and cytokine outputs of mature NK cells and ILCs but are epigenetically poised to do so. Human ILCP robustly generate all ILC subsets in vitro and in vivo. While human ILCP express RAR related orphan receptor C (RORC), circulating ILCP can be found in RORC-deficient patients that retain potential for EOMES+ NK cells, T-BET+ ILC1, GATA-3+ ILC2 and for IL-22+ but not for IL-17A+ ILC3. A model of tissue ILC differentiation (‘ILC-poiesis’) is proposed whereby diverse ILC subsets are generated in situ from ILCP in response to environmental stressors, inflammation and infection.
-
公开(公告)号：US20230183187A1
公开(公告)日：2023-06-15
申请号：US17998436
申请日：2021-05-12
申请人： CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE , INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) , COMMISSARIAT À L'ÉNERGIE ATOIMQUE ET AUX ÉNERGIES ALERNATIVES , UNIVERSITE PARIS-SACLAY , SORBONNE UNIVERSITÉ , ASSOCIATION FRANÇAISE CONTRE LES MYOPATHIES , ASSOCIATION INSTITUT DE MYOLOGIE
发明人： Olivier NAMY , Laure BIDOU , Olivier BUGARD , Jean-Christophe CINTRAT , Goulven MERER , Egor CHIRKIN
IPC分类号： C07D239/84
CPC分类号： C07D239/84
摘要： The present invention relates to the use of at least one compound of formula (I), or one of its pharmaceutically acceptable salts, for preventing and/or treating a disease caused by a nonsense mutation. It also relates to compounds of formula (II) and their uses.
-
-
-
-
-
-
-
-
-
搜索结果
705 条记录 (耗时 0.043 秒)
